Home Cart Sign in  
Chemical Structure| 926927-42-6 Chemical Structure| 926927-42-6

Structure of Toll-like receptor modulator
CAS No.: 926927-42-6

Chemical Structure| 926927-42-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Toll-like receptor modulator is a quinazolinone-derived regulator of both Toll-like receptor and γ-secretase.

Synonyms: Toll-like receptor modulator

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Toll-like receptor modulator

CAS No. :926927-42-6
Formula : C15H13F5N2O2
M.W : 348.27
SMILES Code : O=C(C1=CC2=CC=C(C(F)(F)C(F)(F)F)C=C2N=C(N)C1)OCC
Synonyms :
Toll-like receptor modulator
MDL No. :MFCD11867857
InChI Key :ICZPANLPYRTVSF-UHFFFAOYSA-N
Pubchem ID :15953875

Safety of Toll-like receptor modulator

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Toll-like receptor modulator

pyroptosis
TLR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01294293 Malignant Ovarian Mixed Epithe... More >>lial Tumor Ovarian Brenner Tumor Ovarian Clear Cell Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Undifferentiated Ovarian Carcinoma Less << Phase 1 Completed - United States, Arizona ... More >> Gynecologic Oncology Group of Arizona Phoenix, Arizona, United States, 85012 Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States, 85013 United States, Colorado University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States, 80045 United States, Iowa University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Ohio MetroHealth Medical Center Cleveland, Ohio, United States, 44109 United States, Oklahoma University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Rhode Island Women and Infants Hospital Providence, Rhode Island, United States, 02905 Less <<
NCT01524874 Hypovitaminosis D ... More >> Insulin Resistance Diabetes Less << Not Applicable Completed - United States, Hawaii ... More >> Lokahi Health Center Kailua Kona, Hawaii, United States, 96740 United States, Washington Bastyr University Kenmore, Washington, United States, 98028 Less <<
NCT03736122 Malignant Pleural Effusion ... More >> Malignant Ascites Less << Phase 1 Phase 2 Not yet recruiting January 2022 Australia, South Australia ... More >> Flinders Medical Centre Not yet recruiting Adelaide, South Australia, Australia, 5042 Contact: Kathrina Bartolay    +61 8 8404 2201    Kathrina.Bartolay@sa.gov.au    Principal Investigator: Anand Rose, MD Less <<
NCT02798978 Cancer Phase 1 Completed - Germany ... More >> GSK Investigational Site Berlin, Germany, 14050 Less <<
NCT02643303 Head and Neck Squamous Cell Ca... More >>rcinoma Breast Cancer Sarcoma Merkel Cell Carcinoma Cutaneous T-Cell Lymphoma Melanoma Renal Cancer Bladder Cancer Prostate Cancer Lymphoma, Cutaneous T-Cell Less << Phase 1 Phase 2 Recruiting August 2022 United States, Georgia ... More >> Research Facility Recruiting Atlanta, Georgia, United States, 30322 United States, New York Research Facility Recruiting Buffalo, New York, United States, 14263 Research Facility Recruiting New York, New York, United States, 10029 United States, Ohio Research Facility Recruiting Cleveland, Ohio, United States, 44195 Contact: Shelley Robinson       robinss@ccf.org    United States, Virginia Research Facility Recruiting Charlottesville, Virginia, United States, 22908 Contact: Emily H. Allred, PhD, CCRC       eh4m@virginia.edu Less <<
NCT03172975 Hookworm Infections Phase 2 Recruiting December 30, 2019 United States, District of Col... More >>umbia George Washington University Recruiting Washington, District of Columbia, United States, 20037 Contact: Doreen Campbell, MSc    202-994-8976    hookworm@gwu.edu Less <<
NCT01438333 Chronic Periodontitis Not Applicable Completed - Italy ... More >> University of L'Aquila, Division of Periodontology L'aquila, AQ, Italy, 67100 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.87mL

0.57mL

0.29mL

14.36mL

2.87mL

1.44mL

28.71mL

5.74mL

2.87mL

References

 

Historical Records

Categories